IL1B and COVID-19: Considering the pronounced inflammatory response in COVID-19 and CDI infections, with elevated levels of IL-6, TNF-α, IL-1β, and IP-10, as well as the reported dysbiosis [70–72], FMT could play a crucial role in the treatment of CDI or more severe conditions like COVID-19 and C. difficile co-infections.